287 related articles for article (PubMed ID: 32334387)
1. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
2. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract][Full Text] [Related]
3. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
4. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
[TBL] [Abstract][Full Text] [Related]
5. Rational Design of PLGA Nanoparticle Vaccine Delivery Systems To Improve Immune Responses.
Gu P; Wusiman A; Zhang Y; Liu Z; Bo R; Hu Y; Liu J; Wang D
Mol Pharm; 2019 Dec; 16(12):5000-5012. PubMed ID: 31621331
[TBL] [Abstract][Full Text] [Related]
6. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 TÂ cell immunity.
Chai D; Qiu D; Shi X; Ding J; Jiang N; Zhang Z; Wang J; Yang J; Xiao P; Wang G; Zheng J
Mol Ther Oncolytics; 2022 Mar; 24():1-13. PubMed ID: 34977338
[TBL] [Abstract][Full Text] [Related]
8. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
[TBL] [Abstract][Full Text] [Related]
10. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
[TBL] [Abstract][Full Text] [Related]
11. Polyethylenimine-coated PLGA nanoparticles-encapsulated Angelica sinensis polysaccharide as an adjuvant for H9N2 vaccine to improve immune responses in chickens compared to Alum and oil-based adjuvants.
Gu P; Wusiman A; Zhang Y; Cai G; Xu S; Zhu S; Liu Z; Hu Y; Liu J; Wang D
Vet Microbiol; 2020 Dec; 251():108894. PubMed ID: 33096470
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
Cubillos-Ruiz JR; Engle X; Scarlett UK; Martinez D; Barber A; Elgueta R; Wang L; Nesbeth Y; Durant Y; Gewirtz AT; Sentman CL; Kedl R; Conejo-Garcia JR
J Clin Invest; 2009 Aug; 119(8):2231-44. PubMed ID: 19620771
[TBL] [Abstract][Full Text] [Related]
13. Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8
Chai D; Shan H; Wang G; Zhang Q; Li H; Fang L; Song J; Liu N; Zhang Q; Yao H; Zheng J
Mol Cancer Ther; 2019 Feb; 18(2):323-334. PubMed ID: 30401695
[TBL] [Abstract][Full Text] [Related]
14. Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma.
Sun H; Li J; Hu W; Yan Y; Guo Z; Zhang Z; Chen Y; Yao X; Teng L; Wang X; Li L; Chai D; Zheng J; Wang G
Mol Immunol; 2021 Nov; 139():184-192. PubMed ID: 34560414
[TBL] [Abstract][Full Text] [Related]
15. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
16. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
17. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
Song C; Noh YW; Lim YT
Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
[TBL] [Abstract][Full Text] [Related]
18. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
19. HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8
Shi X; Ding J; Zheng Y; Wang J; Sobhani N; Neeli P; Wang G; Zheng J; Chai D
iScience; 2023 Mar; 26(3):106143. PubMed ID: 36879804
[TBL] [Abstract][Full Text] [Related]
20. The Immunoenhancement Effects of Polyethylenimine-Modified Chinese Yam Polysaccharide-Encapsulated PLGA Nanoparticles as an Adjuvant.
Zhang Y; Gu P; Wusiman A; Xu S; Ni H; Qiu T; Liu Z; Hu Y; Liu J; Wang D
Int J Nanomedicine; 2020; 15():5527-5543. PubMed ID: 32848386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
